Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain SRPT message board posts where the ticker symbol SRPT has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest SRPT SEC Filings

Filings Format Description Filing Date File/Film Number
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-20-042060 Size: 16 KB
2020-07-09
8-K  Documents   Interactive Data Current report, item 5.02
Acc-no: 0001564590-20-031151 (34 Act)  Size: 162 KB
2020-06-30 001-14895
201000517
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-20-038339 Size: 26 KB
2020-06-22
8-K  Documents   Interactive Data Current report, items 5.02, 5.03, 5.07, and 9.01
Acc-no: 0001564590-20-028562 (34 Act)  Size: 246 KB
2020-06-08 001-14895
20948247
8-K  Documents   Interactive Data Current report, items 7.01 and 9.01
Acc-no: 0001564590-20-028560 (34 Act)  Size: 14 MB
2020-06-08 001-14895
20948232
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-20-031881 Size: 12 KB
2020-05-22
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-20-029918 Size: 7 KB
2020-05-15
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001564590-20-021905 (34 Act)  Size: 9 MB
2020-05-06 001-14895
20852541
DEFA14A  Documents Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Acc-no: 0001564590-20-017704 (34 Act)  Size: 273 KB
2020-04-21 001-14895
20805474
DEF 14A  Documents Other definitive proxy statements
Acc-no: 0001564590-20-017698 (34 Act)  Size: 2 MB
2020-04-21 001-14895
20805370
More SRPT SEC Filings


Related news from
Sat, 11 Jul 2020
00:47:19 +0000
Did Hedge Funds Make The Right Call On Sarepta Therapeutics Inc (SRPT) ?
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not […]
Thu, 02 Jul 2020
12:21:23 +0000
The Daily Biotech Pulse: Novartis Settles Lawsuit For $678M, Sarepta In-Licenses Gene Therapy Pre-Treatment, Unity Biotech Outlines Second-Half Catalysts
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1) * AbbVie Inc (NYSE: ABBV) * ADC Therapeutics SA (NYSE: ADCT) * Affimed NV (NASDAQ: AFMD) * Agios Pharmaceuticals Inc (NASDAQ: AGIO) * Akero Therapeutics Inc (NASDAQ: AKRO) (announced positive results for mid-stage study of NASH drug) * Amgen, Inc. (NASDAQ: AMGN) (reacted to a favorable court ruling on its Enbrel patent litigation) * Aptinyx Inc (NASDAQ: APTX) * BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) * Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) * Crispr Therapeutics AG (NASDAQ: CRSP) * Halozyme Therapeutics, Inc. (NASDAQ: HALO) * Hologic, Inc. (NASDAQ: HOLX) * Legend Biotech Corp (NASDAQ: LEGN) * Liminal BioSciences Inc (NASDAQ: LMNL) (announced commencement of convalescent plasma collection from donors who have recovered from COVID-19 and upcoming catalysts) * Natera Inc (NASDAQ: NTRA) * Opko Health Inc. (NASDAQ: OPK) * Pacira Biosciences Inc (NASDAQ: PCRX) * Tandem Diabetes Care Inc (NASDAQ: TNDM) * Twist Bioscience Corp (NASDAQ: TWST) * Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) (announced FDA approval for drug to treat long-chain fatty acid oxidation disorders)Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 1) * ADiTx Therapeutics Inc (NASDAQ: ADTX) * Fusion Pharmaceuticals Inc (NASDAQ: FUSN) * Generation Bio Co (NASDAQ: GBIO) * Hoth Therapeutics Inc (NASDAQ: HOTH) * Iterum Therapeutics PLC (NASDAQ: ITRM) * Repare Therapeutics Inc (NASDAQ: RPTX)Stocks In Focus Novartis Finalizes $678M Settlement In US Lawsuit Over Kickbacks Paid To Doctors Novartis AG (NYSE: NVS) said it has finalized its previously disclosed agreement with the U.S. Attorney's Office for the Southern District of New York, the New York State attorney general and relator Oswald Bilotta resolving a civil suit challenging speaker programs and other promotional events conducted from 2002 through 2011 by Novartis in the U.S.The litigation pertains to Novartis allegedly spending millions of dollars on incentive programs to doctors who steered patients toward drugs from its cardiovascular division in exchange for illegal kickbacks.As part of this settlement, Novartis said it will pay $678 million and has agreed to new corporate integrity obligations with the Office of Inspector General of the Department of Health & Human Services that will change how the company delivers peer-to-peer programs in the U.S. The company said it had fully provisioned for this settlement in July 2019.The stock was down 0.66% at $87.27 premarket Thursday.Merck Closes Licensing Transaction With Ridgeback To Advance COVID-19 Treatment Candidate Merck & Co., Inc. (NYSE: MRK) announced the closing of its collaboration and licensing agreement with antiviral biotech Ridgeback Biotherapeutics following the FTC granting early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.The companies noted that all closing requirements have been completed for the previously announced partnership transaction to advance the development of EIDD-2801, an investigational, orally available antiviral agent in early clinical development for the treatment of patients with COVID-19.The stock was trading 0.87% higher at $78.80 at the time of publication Thursday.See also: The Week Ahead In Biotech (June 28- July 4): Pending Clinical Readouts In Focus During A Short Holiday Week BeiGene Announces Acceptance Of Chinese Regulatory Application For Tislelizumab Label Expansion Beigene Ltd (NASDAQ: BGNE) said the Center for Drug Evaluation of the China National Medical Products Administration has accepted a supplemental new drug application for its anti-PD-1 antibody tislelizumab in patients with previously treated unresectable hepatocellular carcinoma, the most common form of liver cancer.Unity Biotech Announces Second-Half Clinical Catalysts Offering a clinical trial update, Unity Biotechnology Inc (NASDAQ: UBX) said it expects to release top-line 12-week results from Phase 2 study of UBX0101 in osteoarthritis in the third quarter. The company also said it plans to initiate a first-in-human study of UBX1325 in age-related eye diseases in the second half of 2020.Sarepta In-Licenses Pre-Treatment Candidate For Its Gene Therapies For $407.5M Sarepta Therapeutics Inc (NASDAQ: SRPT) and Hansa Biopharma announced an agreement under which Sarepta is granted an exclusive worldwide license to develop and promote imlifidase as a pre-treatment to enable Sarepta gene therapy treatment in Duchenne muscular dystrophy and Limb-girdle muscular dystrophy.Sarepta will pay Hansa $10 million upfront and up to $397.5 million in development, regulatory and sales milestone payments. The agreement calls for Sarepta assuming responsibility for conducting pre-clinical and clinical studies with imlifidase and any subsequent regulatory approvals, and also promoting imlifidase as a pre-treatment to Sarepta's gene therapies following potential approval.Offerings Zomedica Pharmaceuticals Corp (NYSE: ZOM) said it has priced its previously announced public offering of 187.5 million shares of its common stock, together with short-term warrants, to purchase up to 187.5 million common shares at a combined public offering price of 16 cents per share and accompanying warrant.Each common share is being sold in the offering together with one two-year warrant to purchase one common share at an exercise price of 16 cents per common share, the company said. Zomedica expects to raise gross proceeds of $30 million from the offering.The stock was down 33.26% premarket at 15 cents.Neoleukin Therapeutics Inc (NASDAQ: NLTX) said it intends to offer up to 5 million shares of its common stock and, in lieu of common stock, to certain investors pre-funded warrants to purchase shares of its common stock in an underwritten public offering. All of the securities are being offered by the company.The stock slipped 6% to $15.99 in after-hours trading.BioLife Solutions Inc (NASDAQ: BLFS) said it intends to offer shares of its common stock for sale in an underwritten public offering. The company said it expects to use the gross proceeds for general corporate purposes.The stock was down 7.61% premarket at $14.82. Related Link: Gilead Announces Pricing Of Coronavirus Treatment Remdesivir: 'We Believe All Patients Will Have Access'See more from Benzinga * Global Blood Analyst Projects More Than 60% Upside On Receding Sickle Cell Drug Concerns * Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Thu, 02 Jul 2020
11:00:10 +0000
Sarepta Therapeutics Signs Agreement with Hansa Biopharma for Imlifidase
Sarepta Therapeutics, Inc. (SRPT), the leader in precision genetic medicine for rare diseases, today announced an agreement with Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare Immunoglobulin G (IgG) mediated diseases, for imlifidase. Under the terms of the agreement, Sarepta obtains an exclusive, worldwide license to develop and promote imlifidase as a pre-treatment to enable Sarepta gene therapy administration in Duchenne muscular dystrophy (DMD) and Limb-girdle muscular dystrophy (LGMD), for patients who may otherwise not be eligible for treatment.
Tue, 30 Jun 2020
22:15:10 +0000
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics, Inc. (SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2020 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 26 individuals hired by Sarepta in June 2020. The employees received, in the aggregate, options to purchase 27,315 shares of Sarepta's common stock, and in the aggregate, 13,680 restricted stock units (“RSUs”). The options have an exercise price of $160.34 per share, which is equal to the closing price of Sarepta's common stock on June 30, 2020 (the “Grant Date”).
Tue, 30 Jun 2020
12:30:10 +0000
Sarepta Therapeutics Announces Retirement of Sandy Mahatme, Chief Financial Officer and Chief Business Officer
Sarepta Therapeutics, Inc. (SRPT), the leader in precision genetic medicine for rare diseases, today announced the retirement of Sandy Mahatme, Sarepta’s executive vice president, chief financial officer and chief business officer, from the company effective July 10, 2020. The company has commenced a search process to identify the future chief financial officer. During the interim period, the finance and accounting functions will report directly to Sarepta’s Chief Executive Officer, Doug Ingram, and other departments reporting to Mr. Mahatme will be overseen by members of Sarepta’s executive committee.
Mon, 29 Jun 2020
14:06:02 +0000
Sarepta Completes Rolling NDA Submission for New DMD Therapy
Sarepta (SRPT) is seeking accelerated approval for its third exon-skipping therapy, casimersen, for DMD patients.
Fri, 26 Jun 2020
12:30:10 +0000
Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Casimersen (SRP-4045) for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 45
Sarepta Therapeutics, Inc. (SRPT), the leader in precision genetic medicine for rare diseases, today announced the Company has completed the submission of a rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for casimersen (SRP-4045). Casimersen, a phosphorodiamidate morpholino oligomer (PMO), is engineered to treat patients with Duchenne muscular dystrophy (DMD) who have genetic mutations that are amenable to skipping exon 45 of the Duchenne gene.
Tue, 23 Jun 2020
20:05:26 +0000
Sarepta Addressing Gene Therapy Issue With Two Acquisitions
Biotech’s shares trading near all-time high of $172. It is also working on Covid-19 treatment Continue reading...
Tue, 23 Jun 2020
14:27:02 +0000
Sarepta Inks Agreement With Codiak to Develop Gene Therapies
Sarepta (SRPT) and Codiak BioSciences sign agreement to develop potential gene therapies targeting neuromuscular indications using Codiak's engineered exosomes.
Tue, 23 Jun 2020
09:43:32 +0000
Sarepta, Codiak BioSciences Team Up For Neuromuscular Disease Targeting
Sarepta Therapeutics (SRPT) has announced that it has teamed up with Codiak BioSciences to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing and RNA technologies for neuromuscular diseases.According to Sarepta, the engineered exosome approach offers the potential to effectively deliver genetic therapeutics without triggering the adaptive immune response.The two-year agreement includes up to five neuromuscular targets. Codiak is eligible to receive up to $72.5 million in upfront and near-term license payments plus research funding, as well as milestone payments and tiered royalties on future sales. Sarepta is granted an option to any of the candidates developed as part of the research alliance.Exosomes are natural nanoparticles that serve as the body’s intercellular communication system, facilitating the transfer of a wide variety molecular payloads between cells. Through its proprietary engEx Platform, Codiak can design exosomes with precisely engineered properties, incorporate various types of biologically active molecules and direct them to specific cell types.“Codiak’s engEx technology could potentially address some of the limitations of current treatment approaches and offers broad utility across Sarepta’s therapeutic modalities” commented Sarepta CEO Doug Ingram. “Codiak’s exosomes are engineered for precise tissue targeting and offer a non-viral delivery approach with non-immunogenic potential, thus opening up avenues for more efficient delivery and potential re-dosing,” he added.If Sarepta elects to exercise its option on a target, Codiak will be responsible for research and preclinical development through IND preparation, and Sarepta will take charge of clinical development and commercial activities.Shares in Sarepta have spiked 33% year-to-date, and analysts have a bullish Strong Buy consensus on the stock’s outlook. That’s with a $197 average analyst price target (14% upside potential). (See Sarepta stock analysis on TipRanks)However, Oppenheimer’s Hartaj Singh is taking a more cautious approach. He recently reiterated his Hold rating on the stock without a price target, writing “While Sarepta continues to enhance its gene therapy manufacturing scale-up across its platform of programs, we await clarity on several key aspects for the DMD (Duchenne Muscular Dystrophy) program (SRP-9001).”For Singh, success for the name hinges on several key SRP-9001 steps: scale-up (GMP material by July), study 301’s initiation (2H20), study 102’s readout in 1Q21 and what size/scope of 301 data will support a registrational filing.Related News: Sanofi, Translate Bio Ramp Up Billion-Dollar mRNA Vaccine Collaboration Evoke Pharma Pops 86% On FDA Approval Of Gimoti Nasal Spray Apyx Spikes 45% In Pre-Market On Nod To Sell Helium Products In New Countries More recent articles from Smarter Analyst: * The Rise of E-Commerce and Cloud Services Positions Amazon (AMZN) for the Win * Facebook Faces More Ad Boycotts, But This Analyst Expects Minimal Impact * 3 "Strong Buy" Penny Stocks With Explosive Upside Ahead * Heron Therapeutics: HTX-011 Will Eventually Be Approved, Says Analyst
Mon, 22 Jun 2020
12:00:10 +0000
Sarepta Therapeutics and Codiak BioSciences Collaborate to Research and Develop Exosome-Based Therapeutics for Rare Diseases
Sarepta Therapeutics, Inc. (SRPT), the leader in precision genetic medicine for rare diseases, and Codiak BioSciences, Inc., a company at the forefront of advancing engineered exosomes as a new class of biologic medicines, today announced a global research and option agreement to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing and RNA technologies for neuromuscular diseases. The engineered exosome approach offers the potential to effectively deliver genetic therapeutics without triggering the adaptive immune response.
Thu, 18 Jun 2020
12:30:10 +0000
Sarepta Therapeutics and Selecta Biosciences Enter Into Research License and Option Agreement for Selecta’s ImmTOR Immune Tolerance Platform in Neuromuscular Diseases
Sarepta Therapeutics (SRPT), the leader in precision genetic medicine for rare diseases, and Selecta Biosciences, Inc. (SELB) today announced that they have entered into a Research License and Option agreement granting Sarepta an option to license the rights to develop and commercialize Selecta’s immune tolerance platform, ImmTOR™, for use in Duchenne muscular dystrophy (DMD) and certain limb-girdle muscular dystrophies (LGMDs). In advance of exercising its option, Sarepta will conduct research and evaluate the utility of ImmTOR to minimize or prevent the formation of neutralizing antibodies (NAb) to adeno-associated virus (AAV) in connection with the administration of Sarepta’s DMD and LGMD gene therapy candidates.
Tue, 16 Jun 2020
16:00:04 +0000
Sarepta Therapeutics (SRPT) Upgraded to Buy: What Does It Mean for the Stock?
Sarepta Therapeutics (SRPT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Tue, 16 Jun 2020
15:30:03 +0000
Is Sarepta Therapeutics (SRPT) Stock Outpacing Its Medical Peers This Year?
Is (SRPT) Outperforming Other Medical Stocks This Year?
Mon, 15 Jun 2020
20:02:00 +0000
Sarepta's Gene Therapy for Duchenne Muscular Dystrophy Clears a Major Safety Hurdle
Early safety data for the potential one-shot cure for the lethal muscle wasting disorder looks encouraging.
Mon, 15 Jun 2020
15:00:10 +0000
Sarepta Therapeutics Announces Positive Safety and Efficacy Data from the SRP-9001 Micro-Dystrophin Gene Therapy Trial Published in JAMA Neurology
Sarepta Therapeutics, Inc. (SRPT), the leader in precision genetic medicine for rare diseases, today announced safety and tolerability data at one year from four Duchenne muscular dystrophy (DMD) clinical trial participants who received SRP-9001 micro-dystrophin (AAVrh74.MHCK7.micro-dystrophin) have been published in JAMA Neurology. SRP-9001 is an investigational gene transfer therapy intended to deliver its micro-dystrophin-encoding gene to muscle tissue for the targeted production of micro-dystrophin protein.
Tue, 09 Jun 2020
14:34:02 +0000
Sarepta's Gene Therapy Promising in Muscular Dystrophy Study
Sarepta's (SRPT) gene therapy candidate for treating limb-girdle muscular dystrophy shows continued functional improvement over a year for the lower dose as well as increasing efficacy with higher dose.
Tue, 09 Jun 2020
12:59:12 +0000
Sarepta Therapeutics' Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Sarepta Therapeutics.
Mon, 08 Jun 2020
20:15:23 +0000
Sarepta Beats Its Own Gene Therapy Expectations — And Shares Surge
Three children with muscular dystrophy continued to show improvements a year after receiving Sarepta's experimental gene therapy, the biotech said Monday. In response, SRPT stock jumped.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "ValueForum has been a life changer for me. Due to the generosity of a remarkable group of people I quit work at the age of 53 to invest/trade full time. ValueForum is like having a thousand set of eyes watching the markets for you, there is no way an individual working alone could begin to keep up with all the information that as a member of this group you are able to keep up with. Take my right arm but don't take my ValueForum!" more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2020, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards